Ascendis Pharma Q3 2025: Stronger Revenue, Narrower Loss & Promising TransCon PTH Results
Ascendis Pharma Q3 2025 outlook: tighter losses, $213 m revenue, and strong TransCon PTH clinical gains amid a $1.15 bn hypoparathyroidism market.
3 minutes to read

